Brean Murray Downgrades Halozyme Therapeutics (HALO) to Hold
HALO Hot Sheet
Rating Summary:4 Buy, 2 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 22
Brean Murray downgrades Halozyme Therapeutics, Inc. (Nasdaq: HALO) from Buy to Hold, saying while fundamentals are strong, the valuation is rich.
The firm said, "Although we view the fundamentals of the company as strong, we believe the stock is fairly valued at current levels with its recent run-up. Further, in the what we view as an increasingly more competitive diabetic market, we believe a potential insulin product will need to demonstrate substantial additional benefit, including better control of glucose level, benefit in weight loss, better control of hypoglycemia, and long-term safety data in order to justify the increased drug cost and to compete effectively with the currently marketed products and numerous soon-to-be marketed products with novel mechanism of actions or better delivery methods. Since the efficacy data of Halozyme's diabetic product is still early (with only Phase 1 data in healthy volunteers), we will wait for the efficacy data in diabetic patients in order to better assess its market potential."
The firm said, "Although we view the fundamentals of the company as strong, we believe the stock is fairly valued at current levels with its recent run-up. Further, in the what we view as an increasingly more competitive diabetic market, we believe a potential insulin product will need to demonstrate substantial additional benefit, including better control of glucose level, benefit in weight loss, better control of hypoglycemia, and long-term safety data in order to justify the increased drug cost and to compete effectively with the currently marketed products and numerous soon-to-be marketed products with novel mechanism of actions or better delivery methods. Since the efficacy data of Halozyme's diabetic product is still early (with only Phase 1 data in healthy volunteers), we will wait for the efficacy data in diabetic patients in order to better assess its market potential."
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Goldman Sachs Boosts Numbers on PVH Corp (PVH) After Q1 Beat
- Goldman Sachs Cuts Numbers on Tiffany & Co. (TIF) after Weak Q1, Guidance
Create E-mail Alert Related Categories
DowngradesRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
